参考文献/References:
［1］ KLEIN R，CRUICKSHANKS KJ，NASH SD，KRANTZ EM，NIETO FJ，HUANG GH，et al.The prevalence of age-related macular degeneration and associated risk factors［J］.Arch Ophthalmol，2010，128(6)：750-758.
［2］ ZHANG H，LIU ZL.Transforming growth factor-β neutralizing antibodies inhibit subretinal fibrosis in a mouse model［J］.Int J Ophthalmol，2012，5(3)：307-311.
［3］ CHANNA R，SOPHIE R，BAGHERI S，SHAH SM，WANG J，ADEYEMO O，et al.Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes［J］.Am J Ophthalmol，2015，159(1)：9-19.
［4］ BLOCH SB，LUND-ANDERSEN H，SANDER B，LARSEN M.Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab［J］.Am J Ophthalmol，2013，156(1)：116-124.
［5］ BROWN GC，BASHA MM，BROWN MM.Neovascular age-related macular degeneration associated with no light perception［J］.Ophthalmic Surg Lasers Imaging Retina，2015，46(2)：229-234.
［6］ MIERE A，SEMOUN O，COHEN SY，EL AMEEN A，SROUR M，JUNG C，et al.Optical coherence tomography angiography features of subretinal fibrosis in age-related macular degeneration［J］.Retina，2015，35(11)：2275-2284.
［7］ AHLERS CL，GTZINGER E，PIRCHER M，GOLBAZ I，PRAGER F，SCHüTZE C，et al.Imaging of the retinal pigment epithelium in age-related macular degeneration using polarization-sensitive optical coherence tomography［J］.Invest Ophthalmol Vis Sci，2010，51(4)：2149-2157.
［8］ BELKIN M，KALTER-LEIBOVICI O，CHETRIT A，SKAAT A.Time trends in the incidence and causes of blindness in Israel［J］.Am J Ophthalmol，2013，153(2)：214-221.
［9］ YANG Y，TAKEDA A，YOSHIMURA T，OSHIMA Y，SONODA KH，ISHIBASHI T.IL-10 is significantly involved in HSP70-regulation of experimental subretinal fibrosis［J］.PLoS One，2013，8(12)：e80288.
［10］ ZHANG R，LIU Z，ZHANG H，ZHANG Y，LIN D.The COX-2-selective antagonist(NS-398) inhibits choroidal neovascularization and subretinal fibrosis［J］.PLoS One，2016，11(1)：e0146808.
［11］ SINGH A，FABER C，FALK M，NISSEN MH，HVIID TV，RENSEN TL.Altered expression of CD46 and CD59 on leukocytes in neovascular age-related macular degeneration［J］.Am J Ophthalmol，2012，54(1)：193-199.
［12］ ZHANG H，YANG Y，TAKEDA A，YOSHIMURA T，OSHIMA Y，SONODA KH，et al.A novel platelet-activating factor receptor antagonist inhibits choroidal neovascularization and subretinal fibrosis［J］.PLoS One，2013，8(6)：e68173.
［13］ KIMURA K，ORITA T，LIU Y，YANG Y，TOKUDA K，KURAKAZU T，et al.Attenuation of EMT in RPE cells and subretinal fibrosis by an RAR-γ agonist［J］.J Mol Med，2015，93(7)：749-758.
［14］ ROBERTS P，SUGITA M，DEK G，BAUMANN B，ZOTTER S，PIRCHER M，et al.Automated identification and quantification of subretinal fibrosis in neovascular age-related macular degeneration using polarization-sensitive OCT［J］.Invest Ophthalmol Vis Sci，2016，57(4)：1699-1705.
［15］ DANSINGANI KK，TAN AC，GILANI F，PHASUKKIJWATANA N，NOVAIS E，QUERQUES L，et al.Subretinal hyperreflective material imaged with optical coherence tomography angiography［J］.Am J Ophthalmol，2016，169(2)：235-248.
［16］ DANIEL E，TOTH CA，GRUNWALD JE，JAFFE GJ，MARTIN DF，FINE SL，et al.Risk of scar in the comparison of age-related macular degeneration treatments trials［J］.Ophthalmology，2014，121(3)：656-666.
［17］ BLOCH SB.Implementation studies of ranibizumab for neovascular age-related macular degeneration［J］.Acta Ophthalmol，2013，91(7)：1-22.
［18］ ISHIKAWA K，KANNAN R，HINTON DR.Molecular mechanisms of subretinal fibrosis in age-related macular degeneration［J］.Exp Eye Res，2016，142(1)：19-25.
［19］ BATTAGLIA-PARODI M，IACONO P，LA SPINA C，BERCHICCI L，SCOTTI F，LRYS A，et al.Intravitreal bevacizumab for nonsubfoveal choroidal neovascularization associated with angioid streaks［J］.Am J Ophthalmol，2014，157(2)：374-377.
［20］ SINGH A.Systemic changes in neovascular age-related macular degeneration［J］.Dan Med J，2014，61(6)：B4872.
［21］ BARIKIAN A，MAHFOUD Z，ABDULAAL M，SAFAR A，BASHSHUR ZF.Induction with intravitreal bevacizumab every two weeks in the management of neovascular age-related macular degeneration［J］.Am J Ophthalmol，2015，159(1)：131-137.
［22］ COHEN SY，OUBRAHAM H，UZZAN J，DUBOIS L，TADAYONI R.Causes of unsuccessful ranibizumab treatment in exudative age-related macular degeneration in clinical settings［J］.Retina，2012，32(8)：1480-1485.
［23］ SINGH A，FALK MK，SUBHI Y，SRENSEN TL.The association between plasma 25-hydroxyvitamin D and subgroups in age-related macular degeneration：a cross-sectional study［J］.PLoS One，2013，8(7)：e70948.
［24］ CUI W，ZHANG H，LIU ZL.Interleukin-6 receptor blockade suppresses subretinal fibrosis in a mouse model［J］.Int J Ophthalmol，2014，7(2)：194-197.
［25］ HWANG JC，Del PRIORE LV，FREUND KB，CHANG S，IRANMANESH R.Development of subretinal fibrosis after anti-VEGF treatment in neovascular age-related macular degeneration［J］.Ophthalmic Surg Lasers Imaging，2011，42(1)：6-11.
［26］ MATHEW R，PEARCE E，SIVAPRASAD S.Determinants of fixation in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab［J］.Am J Ophthalmol，2012，153(3)：490-496.
［27］ DOLZ-MARCO R，PHASUKKIJWATANA N，SARRAF D，FREUND KB.Regression of type 2 neovascularization into a type 1 pattern after intravitreal anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration［J］.Retina，2017，37(2)：222-233.
［28］ LUO L，ZHANG X，HIRANO Y，TYAGI P，BARABS P，UEHARA H，et al.Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration［J］.ACS Nano，2013，7(4)：3264-3275.
［29］ LECHNER J，CHEN M，HOGG RE，TOTH L，SILVESTRI G，CHAKRAVARTHY U，et al.Higher plasma levels of complement C3a，C4a and C5a increase the risk of subretinal fibrosis in neovascular age-related macular degeneration：Complement activation in AMD［J］.Immun Ageing，2016，13(1)：4.
［30］ LECHNER J，CHEN M，HOGG RE，TOTH L，SILVESTRI G，CHAKRAVARTHY U，et al.Alterations in circulating immune cells in neovascular age-related macular degeneration［J］.Sci Rep，2015，5：16754.
［31］ LIU L，KOU P，ZENG Q，PEI G，LI Y，LIANG H，et al.CD4+T lymphocytes，especially Th2 cells，contribute to the progress of renal fibrosis［J］.Am J Nephrol，2012，36(4)：386-396.
［32］ SHEN CL，SAMATHANAM C，GRAHAM S，DAGDA RY，CHYU MC，DUNN DM.Green tea polyphenols and 1-α-OH-vitamin D3 attenuate chronic inflammation-induced myocardial fibrosis in female rats.Green tea polyphenols and 1-α-OH-vitamin D3 attenuate chronic inflammation-induced myocardial fibrosis in female rats［J］.J Med Food，2012，15(3)：269-277.
［33］ 王春明，冯宇梁，李佳，张明，俞德超.年龄相关性黄斑变性治疗药物研究进展及未来研发方向［J］.眼科新进展，2015，35(6)：597-600.
WANG CM，FENG YL，LI J，ZHANG M，YU DC.Progress in drug treatment development for age-related macular degeneration［J］.Rec Adv Ophthalmol，2015，35(6)：597-600.
相似文献/References:
[1]范姜砾 王雨生 张鹏.湿性年龄相关性黄斑变性患者血浆中相关抗氧化酶水平测定[J].眼科新进展,2012,32(5):000.
[2]王毅 李罗翔 李娟 曾庆华.ApoE基因缺失小鼠视网膜及Bruch膜组织形态观察[J].眼科新进展,2013,33(1):000.
[3]徐新荣 仲路 黄冰林 魏源华 周欣 王玲 王富强.年龄相关性黄斑变性血浆蛋白质组学初步研究[J].眼科新进展,2013,33(2):000.
[4]党亚龙 陈彬川 穆雅林 赵满丽 朱豫.i-MP对产生2型脉络膜新生血管的年龄相关性黄斑变性患者视力及黄斑厚度的影响[J].眼科新进展,2013,33(2):000.
[5]王毅 李罗翔 李进辉 李娟 曾庆华.血脂异常ApoE基因缺失小鼠视网膜色素上皮细胞胞浆内黑色素和脂褐素的改变[J].眼科新进展,2013,33(7):000.
[6]罗文婷 孙大卫.血管黏附蛋白-1在眼科疾病中的研究进展[J].眼科新进展,2013,33(8):000.
[7]陆秉文 吴星伟.光动力疗法治疗年龄相关性黄斑变性的研究进展[J].眼科新进展,2013,33(4):000.
[8]栾兰 姚勇.湿性年龄相关性黄斑变性的治疗进展[J].眼科新进展,2013,33(4):000.
[9]胡艳红 祁明信 郭娜 陈胜 柯发杰.渗出型年龄相关性黄斑变性患者外周血CCR3的表达[J].眼科新进展,2013,33(11):000.
[10]金鑫,张红.MicroRNA在年龄相关性黄斑变性发病中的作用[J].眼科新进展,2014,34(8):787.[doi:10.13389/j.cnki.rao.2014.0218]
JIN Xin,ZHANG Hong.Role of microRNA in pathogenesis of agerelated macular degeneration[J].Recent Advances in Ophthalmology,2014,34(6):787.[doi:10.13389/j.cnki.rao.2014.0218]